Cargando…

Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice

BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Recuenco, Frances C, Takano, Ryo, Chiba, Shiori, Sugi, Tatsuki, Takemae, Hitoshi, Murakoshi, Fumi, Ishiwa, Akiko, Inomata, Atsuko, Horimoto, Taisuke, Kobayashi, Yoshiyasu, Horiuchi, Noriyuki, Kato, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295290/
https://www.ncbi.nlm.nih.gov/pubmed/25495520
http://dx.doi.org/10.1186/1475-2875-13-487
_version_ 1782352818457280512
author Recuenco, Frances C
Takano, Ryo
Chiba, Shiori
Sugi, Tatsuki
Takemae, Hitoshi
Murakoshi, Fumi
Ishiwa, Akiko
Inomata, Atsuko
Horimoto, Taisuke
Kobayashi, Yoshiyasu
Horiuchi, Noriyuki
Kato, Kentaro
author_facet Recuenco, Frances C
Takano, Ryo
Chiba, Shiori
Sugi, Tatsuki
Takemae, Hitoshi
Murakoshi, Fumi
Ishiwa, Akiko
Inomata, Atsuko
Horimoto, Taisuke
Kobayashi, Yoshiyasu
Horiuchi, Noriyuki
Kato, Kentaro
author_sort Recuenco, Frances C
collection PubMed
description BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood–brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. METHODS: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood–brain barrier integrity. RESULTS: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. CONCLUSION: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA.
format Online
Article
Text
id pubmed-4295290
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42952902015-01-16 Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice Recuenco, Frances C Takano, Ryo Chiba, Shiori Sugi, Tatsuki Takemae, Hitoshi Murakoshi, Fumi Ishiwa, Akiko Inomata, Atsuko Horimoto, Taisuke Kobayashi, Yoshiyasu Horiuchi, Noriyuki Kato, Kentaro Malar J Research BACKGROUND: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood–brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. METHODS: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood–brain barrier integrity. RESULTS: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. CONCLUSION: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA. BioMed Central 2014-12-11 /pmc/articles/PMC4295290/ /pubmed/25495520 http://dx.doi.org/10.1186/1475-2875-13-487 Text en © Recuenco et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Recuenco, Frances C
Takano, Ryo
Chiba, Shiori
Sugi, Tatsuki
Takemae, Hitoshi
Murakoshi, Fumi
Ishiwa, Akiko
Inomata, Atsuko
Horimoto, Taisuke
Kobayashi, Yoshiyasu
Horiuchi, Noriyuki
Kato, Kentaro
Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title_full Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title_fullStr Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title_full_unstemmed Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title_short Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
title_sort lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by plasmodium berghei anka in balb/c mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295290/
https://www.ncbi.nlm.nih.gov/pubmed/25495520
http://dx.doi.org/10.1186/1475-2875-13-487
work_keys_str_mv AT recuencofrancesc lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT takanoryo lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT chibashiori lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT sugitatsuki lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT takemaehitoshi lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT murakoshifumi lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT ishiwaakiko lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT inomataatsuko lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT horimototaisuke lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT kobayashiyoshiyasu lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT horiuchinoriyuki lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice
AT katokentaro lambdacarrageenantreatmentexacerbatestheseverityofcerebralmalariacausedbyplasmodiumbergheiankainbalbcmice